Surface Oncology (SURF) priced an upsized IPO at the high end of its range. That is normally a strong buy signal, but Surface dropped 11% on its Thursday debut. It is the year's worst first-day drop for a biotech, and the fourth-worst overall....read more
Surface Oncology, which is developing next-generation cancer therapies to boost the immune system, raised $108 million by offering an upsized 7.2 million shares at $15, the high end of the $13 to $15 range. The Cambridge, MA-based company originally filed to...read more
Eight deals are on the calendar for the week ahead looking to raise a combined $2.6 billion. Headlining the week is DellEMC spin-off Pivotal Software, which provides a platform for enterprises to manage cloud-based apps. The company is...read more
US IPO Weekly Recap: Pivotal Software gains 5% as 5 IPOs price and 3 delay
• 8 IPOs had planned to raising $2.6 billion, but instead 5 IPOs raised $1.4 billion • Despite tech sector's strength, top-performer Pivotal Software gained just 5%; week averaged 2% •...read more
SURF's up... then down: Surface Oncology prices upsized IPO and drops 11%
Surface Oncology (SURF) priced an upsized IPO at the high end of its range. That is normally a strong buy signal, but Surface dropped 11% on its Thursday debut. It is the year's worst first-day drop for a biotech, and the fourth-worst overall....read more
Surface Oncology prices upsized IPO at $15, the high end of the range
Surface Oncology, which is developing next-generation cancer therapies to boost the immune system, raised $108 million by offering an upsized 7.2 million shares at $15, the high end of the $13 to $15 range. The Cambridge, MA-based company originally filed to...read more
US IPO Week Ahead: A pivotal week with 8 IPOs
Eight deals are on the calendar for the week ahead looking to raise a combined $2.6 billion. Headlining the week is DellEMC spin-off Pivotal Software, which provides a platform for enterprises to manage cloud-based apps. The company is...read more